Sonothrombolysis with Magnetically Targeted Microbubbles.

Ultrasound Med Biol

Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, United Kingdom. Electronic address:

Published: May 2019


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Microbubble-enhanced sonothrombolysis is a promising approach to increasing the tolerability and efficacy of current pharmacological treatments for ischemic stroke. Maintaining therapeutic concentrations of microbubbles and drugs at the clot site, however, poses a challenge. The objective of this study was to investigate the effect of magnetic microbubble targeting upon clot lysis rates in vitro. Retracted whole porcine blood clots were placed in a flow phantom of a partially occluded middle cerebral artery. The clots were treated with a combination of tissue plasminogen activator (0.75 µg/mL), magnetic microbubbles (∼10 microbubbles/mL) and ultrasound (0.5 MHz, 630-kPa peak rarefactional pressure, 0.2-Hz pulse repetition frequency, 2% duty cycle). Magnetic targeting was achieved using a single permanent magnet (0.08-0.38 T and 12-140 T/m in the region of the clot). The change in clot diameter was measured optically over the course of the experiment. Magnetic targeting produced a threefold average increase in lysis rates, and linear correlation was observed between lysis rate and total energy of acoustic emissions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ultrasmedbio.2018.12.014DOI Listing

Publication Analysis

Top Keywords

lysis rates
8
magnetic targeting
8
sonothrombolysis magnetically
4
magnetically targeted
4
targeted microbubbles
4
microbubbles microbubble-enhanced
4
microbubble-enhanced sonothrombolysis
4
sonothrombolysis promising
4
promising approach
4
approach increasing
4

Similar Publications

Introduction Patients have identified knee stiffness as a factor contributing to postoperative dissatisfaction after total knee arthroplasty (TKA). Losartan is an angiotensin receptor blocker (ARB) that has demonstrated antifibrotic effects; however, the impact of perioperative losartan on arthrofibrosis after TKA is not well understood. Therefore, the purpose of this study was to determine if losartan exhibits antifibrotic benefits in patients who undergo TKA by decreasing the rates of manipulation under anesthesia (MUA), when compared to patients who are not taking losartan.

View Article and Find Full Text PDF

When pathogenic bacteria colonize a wound, they can create an alkaline ecological niche that selects for their survival by creating an inflammatory environment restricting healthy wound healing to proceed. To aid healing, wound acidification has been exploited to disrupt this process and stimulate fibroblast growth, increase wound oxygen concentrations, minimize proteolytic activity, and restimulate the host immune system. Within this study, we have developed cobalt-doped carbon quantum dot nanoparticles that work together with mild acetic acid, creating a potent synergistic antimicrobial therapy.

View Article and Find Full Text PDF

Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.

View Article and Find Full Text PDF

Pediatric hemodialysis is a life-saving treatment for children with chronic kidney diseases. Central venous catheters (CVCs) are the most commonly used vascular access, despite being commonly subject to complications leading to inadequate hemodialysis and catheter replacement. The available CVCs feature various design elements reflecting ongoing efforts to achieve optimal performance.

View Article and Find Full Text PDF

Background: Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) face a poor prognosis in the absence of effective treatment options. Ibrutinib plus venetoclax demonstrated high response rates and a tolerable safety profile in the primary analysis of the Phase 2, M20-075 study (NCT04477486) in Japanese patients with R/R MCL. We report updated efficacy and safety from this study with longer follow-up.

View Article and Find Full Text PDF